The Sift No.1

Analytical Perspectives on Equity Selection and Market Data.

NKTR: "Winning By Being Second"

Why Nektar Therapeutics atopic dermatitis (AtD) drug could be significantly undervalued despite being a potential second-line drug treatment option

CGCM Q1'26 Quarterly Letter

Part 2: Q4 Earnings Update On High Conviction Investment - EVLV

Quick update on EVLV and why we think that FY'26 guide hints at a long-term opportunity for price appreciation above $10/share.

Part 1: Q4 Earnings Updates and Capturing Cheap Growth? [REAL, KITS, WW]

Going over Q4'25 earnings for current investors and why they might standout for new investors looking new areas for capital deployment

LNSR Terminates Deal - Is It Worth More Than the $14/Share?

A quick walkthrough on the math post-deal break, and could LNSR still be compelling as a standalone company?

Understanding "Risk" From One of the Greats — Howard Marks

What one of the best investors on Wall Street has to say about "risk" and what we can learn from it

NVO's Pressure Forces HIMS to Pivot

What both bulls and bears need to understand is the financial impact of HIMS pivoting hard from the compounded GLP-1 strategy

IPO Notes: Unprofitable Once Upon A Farm (OFRM) Goes Public

Taking a look at the recent OFRM IPO, co-founded by actress Jennifer Garner, and why it could be an interesting setup for the newest CPG brand to hit the market

Quick Special Situation: Restaurant Take-Private w/ Potential Bidding War

Why this prized restaurant asset could strike up a bidding war amongst bidders looking to shore up their position in the quick service restaurant (QSR) space. Potential return could be in excess of 35%.